Skip to main content
. 2008 Apr 3;111(12):5477–5485. doi: 10.1182/blood-2008-01-132837

Figure 1.

Figure 1

EFS of all patients enrolled on 9900 series therapeutic studies with satisfactory end-induction MRD. The 5-year EFS values plus or minus SE are shown for patients with varying levels of MRD. The outcome of those with high levels of MRD is very poor, but even those with 0.01% to 0.1% MRD have only a 59% plus or minus 5% 5-year EFS.